Immunohistochemical evaluation of Ki-67 expression, together with the assessment of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) levels, is used to define different subtypes of breast cancer [32]. The gene discussed is MKI67; the disease is breast carcinoma.